BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15225422)

  • 1. [Investigation on the alteration of hepatitis B virus (HBV) markers in liver allograft of HBV related recipients in perioperative period].
    Dai J; Lu SC; Yan LN; Li B; Lai W; Liu J; Zhao J; Wen TF; Gui M; Lin QY; Wang WY; Zhang XH
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):331-3. PubMed ID: 15225422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report.
    Lu SC; Yan LN; Li B; Ma YK; Liu C; Wen TF; Lin QY; Zhao JC; Wang XB; Li XD; Qing S; Zhao LS; Liu C; Liu J; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):196-201. PubMed ID: 14599968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
    Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
    Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.
    Sawyer RG; McGory RW; Gaffey MJ; McCullough CC; Shephard BL; Houlgrave CW; Ryan TS; Kuhns M; McNamara A; Caldwell SH; Abdulkareem A; Pruett TL
    Ann Surg; 1998 Jun; 227(6):841-50. PubMed ID: 9637547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An analysis of long term prophylaxis of virus recurrence with antiviral treatment in HBV infected liver transplant recipient patients].
    Dai J; Lu SC; Yan LN; Li B; Lai W; Zhao J; Jin SJ; Wen TF; Zhao JC; Zeng Y; Gu M; Tao CM; Zhang XH
    Zhonghua Gan Zang Bing Za Zhi; 2007 Sep; 15(9):663-6. PubMed ID: 17903367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.
    Yoshida EM; Erb SR; Partovi N; Scudamore CH; Chung SW; Frighetto L; Eggen HJ; Steinbrecher UP
    Liver Transpl Surg; 1999 Nov; 5(6):520-5. PubMed ID: 10545541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    van Nunen AB; de Man RA; Heijtink RA; Vossen AC; Schalm SW
    J Viral Hepat; 2002 May; 9(3):221-8. PubMed ID: 12010511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis.
    Roche B; Feray C; Gigou M; Roque-Afonso AM; Arulnaden JL; Delvart V; Dussaix E; Guettier C; Bismuth H; Samuel D
    Hepatology; 2003 Jul; 38(1):86-95. PubMed ID: 12829990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
    Wang ZX; Ding GS; Fu H; Zhang JJ; Chen XS; Guo WY; Shi XM; Fu ZR
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):345-8. PubMed ID: 15313666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the changes of HBV serum markers and HBV DNA and the effects of perioperative factors after liver transplantation].
    Tang YM; Chen GH; He XS; Zhu XF; Chen MH
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):164-7. PubMed ID: 15760545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.